248 related articles for article (PubMed ID: 33207545)
1. Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact.
Noguchi T; Iwahashi N; Sakai K; Matsuda K; Matsukawa H; Toujima S; Nishio K; Ino K
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33207545
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing.
Iwahashi N; Sakai K; Noguchi T; Yahata T; Matsukawa H; Toujima S; Nishio K; Ino K
Sci Rep; 2019 Jul; 9(1):10426. PubMed ID: 31320709
[TBL] [Abstract][Full Text] [Related]
3. The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer.
Cai J; Jiang H; Li S; Yan X; Wang M; Li N; Zhu C; Dong H; Wang D; Xu Y; Xie H; Wu S; Lou J; Zhao J; Li Q
Front Oncol; 2021; 11():751106. PubMed ID: 35273907
[TBL] [Abstract][Full Text] [Related]
4. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
Yang M; Topaloglu U; Petty WJ; Pagni M; Foley KL; Grant SC; Robinson M; Bitting RL; Thomas A; Alistar AT; Desnoyers RJ; Goodman M; Albright C; Porosnicu M; Vatca M; Qasem SA; DeYoung B; Kytola V; Nykter M; Chen K; Levine EA; Staren ED; D'Agostino RB; Petro RM; Blackstock W; Powell BL; Abraham E; Pasche B; Zhang W
J Hematol Oncol; 2017 May; 10(1):100. PubMed ID: 28472989
[TBL] [Abstract][Full Text] [Related]
5. Hybrid Capture-based Genomic Profiling of Circulating Tumor DNA From Patients With Advanced Ovarian
Shen W; Shan B; Liang S; Zhang J; Yu Y; Zhang Y; Wang G; Bai Y; Qian B; Lu J; Jiang Z
Pathol Oncol Res; 2021; 27():581534. PubMed ID: 34257528
[No Abstract] [Full Text] [Related]
6. Mutations in circulating tumor DNA detected in the postoperative period predict poor survival in patients with ovarian cancer.
Chao A; Chen SJ; Chen HC; Tan KT; Hsiao W; Jung SM; Yang LY; Huang KG; Chou HH; Huang HJ; Chang TC; Chao AS; Lee YH; Wu RC; Lai CH
Biomed J; 2023 Oct; 46(5):100563. PubMed ID: 36208860
[TBL] [Abstract][Full Text] [Related]
7. Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer.
Watanabe T; Nanamiya H; Endo Y; Kojima M; Nomura S; Furukawa S; Soeda S; Tamura H; Ryufuku M; Tanaka D; Isogai T; Imai JI; Watanabe S; Fujimori K
J Ovarian Res; 2021 Oct; 14(1):129. PubMed ID: 34615547
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive gene mutation analysis of liquid biopsy samples from patients with metastatic colorectal cancer to the ovary: A case report.
Iwahashi N; Sakai K; Noguchi T; Yahata T; Toujima S; Nishio K; Ino K
Oncol Lett; 2018 Nov; 16(5):6431-6436. PubMed ID: 30405780
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].
Jin Y; Chen YM; Hu X; Tang HR; Yu XM; Fan Y; Xu YJ; Xu HM; Li PS; Li Q; Chang LP; Guan YF; Chen M
Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3614-3621. PubMed ID: 33333686
[No Abstract] [Full Text] [Related]
10. Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP-Seq in neoadjuvant chemotherapy-treated advanced ovarian cancer.
Noguchi T; Sakai K; Iwahashi N; Matsuda K; Matsukawa H; Yahata T; Toujima S; Nishio K; Ino K
Oncol Lett; 2020 Apr; 19(4):2713-2720. PubMed ID: 32218822
[TBL] [Abstract][Full Text] [Related]
11. Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial.
Sabatier R; Garnier S; Guille A; Carbuccia N; Pakradouni J; Adelaide J; Provansal M; Cappiello M; Rousseau F; Chaffanet M; Birnbaum D; Mamessier E; Gonçalves A; Bertucci F
Front Oncol; 2022; 12():946257. PubMed ID: 35965534
[TBL] [Abstract][Full Text] [Related]
12. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.
Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA
J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy.
Yang W; Zou J; Li Y; Liu R; Yan Z; Chen S; Zhao X; Guo W; Huang M; Li W; Zhu X; Chen Z
Front Oncol; 2022; 12():830816. PubMed ID: 35280779
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
Fan G; Zhang K; Ding J; Li J
Oncotarget; 2017 May; 8(20):33922-33932. PubMed ID: 28430611
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients.
Yang YC; Wang D; Jin L; Yao HW; Zhang JH; Wang J; Zhao XM; Shen CY; Chen W; Wang XL; Shi R; Chen SY; Zhang ZT
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29914973
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
Kim YM; Lee SW; Lee YJ; Lee HY; Lee JE; Choi EK
J Gynecol Oncol; 2019 May; 30(3):e32. PubMed ID: 30887755
[TBL] [Abstract][Full Text] [Related]
18. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
Hicks JK; Saller J; Wang E; Boyle T; Gray JE
Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
[TBL] [Abstract][Full Text] [Related]
19. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
Ding PN; Becker TM; Bray VJ; Chua W; Ma YF; Lynch D; Po J; Luk AWS; Caixeiro N; de Souza P; Roberts TL
Lung Cancer; 2019 Aug; 134():187-193. PubMed ID: 31319980
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay.
Remon J; Swalduz A; Planchard D; Ortiz-Cuaran S; Mezquita L; Lacroix L; Jovelet C; Rouleau E; Leonce C; De Kievit F; Morris C; Jones G; Mercier K; Howarth K; Green E; Pérol M; Saintigny P; Besse B
PLoS One; 2020; 15(6):e0234302. PubMed ID: 32525942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]